MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Pleural

Malignant pleural mesothelioma; mesothelioma of the lining of the lungs, or pleura.

Pemetrexed-conjugated hyaluronan for the treatment of malignant pleural mesothelioma.

European Journal of Pharmaceutical Sciences 2019 July 11 [Link] Amano Y, Ohta S, Sakura KL, Ito T Abstract Pemetrexed (PMX) is a multi-targeted antifolate drug used for the treatment of malignant pleural mesothelioma (MPM) and non-small cell lung cancer. Hyaluronan (HA) in blood is well known as a disease marker of MPM. We synthesized PMX-conjugated […]

Comments Off on Pemetrexed-conjugated hyaluronan for the treatment of malignant pleural mesothelioma.

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.

CA 2019 July 8 [Link] Carbone M, Adusumilli PS, Alexander HR Jr, Baas P, Bardelli F, Bononi A, Bueno R, Felley-Bosco E, Galateau-Salle F, Jablons D, Mansfield AS10, Minaai M, de Perrot M, Pesavento P, Rusch V, Severson DT, Taioli E, Tsao A, Woodard G, Yang< H, Zauderer MG, Pass HI/strong> Abstract Mesothelioma affects mostly […]

Comments Off on Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.

Pleurectomy/decortication and hyperthermic intrathoracic chemoperfusion using cisplatin and doxorubicin for malignant pleural mesothelioma.

Journal of Thoracic Disease 2019 May [Link] Klotz LV, Lindner M, Eichhorn ME, Grützner U, Koch I, Winter H, Kauke T, Duell T, Hatz RA Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive malignancy with few long-term survivors. Despite the dismal prognosis, hyperthermic intrathoracic chemoperfusion (HITHOC) was shown to improve survival in a selective […]

Comments Off on Pleurectomy/decortication and hyperthermic intrathoracic chemoperfusion using cisplatin and doxorubicin for malignant pleural mesothelioma.

Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.

Clinical Lung Cancer 2019 May 13 [Link] Brosseau S, Danel C, Scherpereel A, Mazières J, Lantuejoul S, Margery J, Greillier L, Audigier-Valette C, Gounant V, Antoine M, Moro-Sibilot D, Rouquette I, Molinier O, Corre R, Monnet I, Langlais A, Morin F, Bergot E, Zalcman G, Levallet G Abstract BACKGROUND: Anticancer immune responses are negatively regulated […]

Comments Off on Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.

Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma.

Lung 2019 July 2 [Link] Jiménez-Ramírez C, Casjens S, Juárez-Pérez CA, Raiko I, Del Razo LM, Taeger D, Calderón-Aranda ES, Rihs HP, Acosta-Saavedra LC, Weber DG, Cabello-López A, Pesch B, Ochoa-Vázquez MD, Burek K, Torre-Bouscoulet L, Pérez-Padilla JR, García-Bazan EM, Brüning T, Johnen G, Aguilar-Madrid G Abstract PURPOSE: Malignant pleural mesothelioma (MPM) is a highly […]

Comments Off on Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma.

What can independent research for mesothelioma achieve to treat this orphan disease?

Expert Opinion on Investigational Drugs 2019 July 1 [Link] Guazzelli A, Meysami P, Bakker E, Bonanni E, Demonacos C, Krstic-Demonacos M, Mutti L Abstract Introduction: Malignant pleural mesothelioma (MPM) is a rare neoplasm with a poor prognosis, as current therapies are ineffective. Despite the increased understanding of the molecular biology of mesothelioma, there is still […]

Comments Off on What can independent research for mesothelioma achieve to treat this orphan disease?

Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy for Treatment of Malignant Pleural Mesothelioma.

Clinical Cancer Research 2019 July 1 [Link] Hassan R, Alley E, Kindler H, Antonia SJ, Jahan TM, Honarmand S, Nair N, Whiting C, Enstrom A, Lemmens E, Tsujikawa T, Kumar S, Choe G, Thomas A, McDougall K, Murphy A, Jaffee EM, Coussens LM, Brockstedt DG Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive cancer […]

Comments Off on Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy for Treatment of Malignant Pleural Mesothelioma.

2-Deoxy-glucose Enhances the Effect of Cisplatin and Pemetrexed in Reducing Malignant Pleural Mesothelioma Cell Proliferation But Not Spheroid Growth.

Anticancer Research 2019 July [Link] Gerogianni I, Pitaraki E, Jagirdar RM, Kouliou O, Giannakou L, Giannopoulos S, Papazoglou E, Hatzoglou C, Gourgoulianis KI, Zarogiannis SG Abstract BACKGROUND/AIM: Malignant pleural mesothelioma (MPM) is a therapy-resistant neoplasm of the pleura. Standard chemotherapy consists of a combination of cisplatin (CPDD) and pemetrexed (PEM). The aim of this study […]

Comments Off on 2-Deoxy-glucose Enhances the Effect of Cisplatin and Pemetrexed in Reducing Malignant Pleural Mesothelioma Cell Proliferation But Not Spheroid Growth.

Long term survival and perioperative propensity score matched outcomes of diaphragmatic resections compared to stripping in cytoreductive surgery + intra-peritoneal chemotherapy.

American Journal of Surgery 2019 June 23 [Link] Singh B, Singh G, Alzahrani N, Morris DL Abstract OBJECTIVES: To assess the impact of short and long term outcomes of diaphragm resection and repair in cyto-reductive surgery (CRS) and intra-peritoneal chemotherapy (IPC). METHODS: 1230 consecutive CRS/IPC procedures were performed between 1996 and 2018 in Sydney, Australia. […]

Comments Off on Long term survival and perioperative propensity score matched outcomes of diaphragmatic resections compared to stripping in cytoreductive surgery + intra-peritoneal chemotherapy.

Synergistic enhancement of cellular uptake with CD44-expressing malignant pleural mesothelioma by combining cationic liposome and hyaluronic acid-lipid conjugate.

Journal of Pharmaceutical Sciences 2019 June 20 [Link] Sakurai Y, Kato A, Hida Y, Hamada J, Maishi N, Hida K, Harashima H Abstract Malignant pleural mesothelioma (MPM) is a highly aggressive form of cancer, with a median survival of less than one year. It is well known that the hyaluronan (HA) receptor CD44 is highly […]

Comments Off on Synergistic enhancement of cellular uptake with CD44-expressing malignant pleural mesothelioma by combining cationic liposome and hyaluronic acid-lipid conjugate.